First Patient Treated in Myra Vision’s U.S. ADAPT Clinical Study for Glaucoma
Bringing
Innovation
To Glaucoma Care
Dedicated to preserving vision in patients with glaucoma1-3
Bringing
Aiming to advance the future of glaucoma care with the Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System’s control through unprecedented adjustable outflow
Targeting an unmet need
Every patient with glaucoma is unique, and their surgical options should be adaptable to meet their individual treatment needs over time.3,4 Conventional therapies such as trabeculectomy and tube shunts, while effective, may place patients at an increased risk for complications.5,6 That’s why Myra Vision is focusing on bringing you the Calibreye TGT System.
The Calibreye TGT Surgical System is intended to offer an adjustable solution to control IOP in patients with glaucoma, with the following potential benefits:
Options for IOP Control7
Adjustable outflow as a patient’s individual treatment needs change
Safety Without Sacrificing Efficacy7
Developed to provide personalized therapy while minimizing complications
Familiar Delivery Technique7
Implanted via well-established ab externo delivery
Known
MaterialS7-9
Utilizes materials with a long history of safely being used in the eye for glaucoma treatment
Designed to offer a safe solution to control IOP7
The innovative system is engineered to put outflow control in the hands of ophthalmologists who care for patients with glaucoma and give them the opportunity to provide personalized therapy while minimizing complications.
The Calibreye Shunt’s four settings allow for titratable outflow.
View Implantation
View TITRATION
Low-profile design and material properties of the Calibreye Shunt are believed to assist with conforming to the shape of the eye1
Engineered to optimize IOP management with7:
- 10.0 x 1.6–mm overall dimensions intended to provide posterior bleb formation to increase aqueous drainage
- Low profile (0.30 mm thick) to help maximize patient comfort and minimize erosion risk
- Suture eyelets for a secure shunt placement
- Visual indication for confirmation of channel settings
Materials with well-known ophthalmic biocompatibility:
- Silicone
- Hydrophobic properties help reduce protein binding to minimize cellular adhesion10
- Flexible and stable polymer with minimal biodegradation in vivo11
- Hyperemia is milder than with stainless steel11
- Inflammatory response is milder than with polypropylene used in other devices11
- Valve components composed of nitinol, a material with a proven history of use in ocular applications4
About Myra Vision
Myra Vision is a dynamic organization committed to bringing personalized glaucoma care to the surgical armamentarium by delivering an adjustable solution for patients who are candidates for surgery.
Backed by excellence
We are privileged to be a portfolio company of Shifamed, a highly specialized medical technology innovation hub. Since 2007, Shifamed has been at the forefront of medtech innovation, addressing critical healthcare challenges through technology, perseverance and partnership.
Latest News
Myra Vision Secures FDA Approval to Initiate US IDE Study in Glaucoma
Myra Vision Announces Positive Initial Outcomes from its Feasibility Study at the 2025 American Glaucoma Society Meeting
Myra Vision Announces Successful First-In-Human Use of its Calibreye™ System, a Next Generation Aqueous Shunt Therapy for Patients with Moderate to Severe Glaucoma
Myra Vision, a Shifamed Portfolio Company, Closes $25M in Series B Financing
Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings
Myra Medical, A Shifamed Portfolio Company, Closes $3M In Seed Financing
See what Myra Vision is
Up to at these Key Events
References: 1. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440. 2. Leske MC, Heijl A, Hyman L, et al; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965-1972. 3. Jayaram H. Intraocular pressure reduction in glaucoma: does every mmHg count? Taiwan J Ophthalmol. 2020;10(4):255-258. 4. Harasymowycz P, Birt C, Gooi P, et al. Medical management of glaucoma in the 21st century from a Canadian perspective. J Ophthalmol. 2016;6509809. 5. Cursiefen C, Cordeiro F, Cunha-Vaz J, Wheeler-Schilling T, Scholl HPN; EVI Steering Board. Unmet needs in ophthalmology: a European Vision Institute-consensus roadmap 2019-2025. Ophthalmic Res. 2019;62(3):123-133. 6. Sheybani A, Scott R, Samuelson TW, et al. Open-angle glaucoma: burden of illness, current therapies, and the management of nocturnal IOP variation. Ophthalmol Ther. 2020;9(1):1-14. 7. Data on file. Myra Vision; 2023. 8. Lim KS, Allan BD, Lloyd AW, Muir A, Khaw PT. Glaucoma drainage devices; past, present, and future. Br J Ophthalmol. 1998;82(9):1083-1089. 9. Samet S, Ong JA, Ahmed IIK. Hydrus microstent implantation for surgical management of glaucoma: a review of design, efficacy and safety. Eye Vis (Lond). 2019;6:32. 10. Windhövel C, Harder L, Bach JP, et al. Comparison of six different silicones in vitro for application as glaucoma drainage device. Materials (Basel). 2018;11(3):341. 11. Nakamura K, Fujimoto T, Okada M, et al. Tissue reactivity to, and stability of, glaucoma drainage device materials placed under rabbit conjunctiva. Transl Vis Sci Technol. 2022;11(4):9.